Literature DB >> 30971779

Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects.

Elizabeth A de Kort1, Suzanne van Dorp1, Nicole M A Blijlevens1, Walter J F M van der Velden2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30971779     DOI： 10.1038/s41409-019-0526-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  1 in total

1.  Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin.

Authors:  S A Weisdorf; L M Salati; J A Longsdorf; N K Ramsay; H L Sharp
Journal:  Gastroenterology       Date:  1983-11       Impact factor: 22.682
  1 in total
  1 in total

1.  Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.

Authors:  Liping Dou; Bo Peng; Xin Li; Lu Wang; Mingyu Jia; Lingmin Xu; Fei Li; Daihong Liu
Journal:  Trials       Date:  2022-06-06       Impact factor: 2.728
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.